Frier Levitt

Overview

National boutique law firm providing regulatory, transactional, and litigation counsel exclusively to healthcare, life sciences, and pharmacy clients. Represents providers like physicians, pharmacies (specialty, compounding, infusion), labs, hospitals in compliance, PBM disputes, M&A, FDA matters. Does not offer pharma services like hub services or copay programs; instead provides legal services to pharma ecosystem participants, primarily on the provider/pharmacy side rather than directly to pharmaceutical companies.

Services & Capabilities

• Healthcare regulatory compliance, PBM audit defense and litigation, pharmacy law (340B, accreditation, DIR fees), M&A and transactions for healthcare entities, FDA/DEA compliance, litigation against PBMs/payors, formation of MSOs/DSOs/CINs, government affairs/advocacy for pharmacy associations

Competitive Position

• Exclusive focus on healthcare/life sciences/pharmacy law
• attorneys who are licensed clinicians/pharmacists
• deep expertise in PBM disputes and pharmacy regulatory issues

Recent Developments

Launched Regenerative Medicine practice (2025) NJBIZ; Tier 1 Health Care Law ranking (2026) Frier Levitt; 17 attorneys named NJ Super Lawyers (2026); webinars on GLP-1 compounding, PBM reform. No major client wins, funding, or partnerships.

Client & Partner Ecosystem

General Counsel to New Jersey Chapter American Academy of Pediatrics (NJAAP); represented Brooksville Pharmaceuticals (vs. Novo Nordisk); state/national pharmacy associations; various independent/spec

Technology Platform

None

Therapeutic Focus

broad/all

Target Customers

Healthcare providers (physicians/practices, specialty pharmacies, compounding pharmacies, labs, hospitals), pharmacy associations, wholesalers/distributors, private equity investors in healthcare

Sources

• Frier Levitt Website, LinkedIn Company Page, Growjo Profile, NJAAP, Press Release on Relocation, Litigation Win vs Novo Nordisk